|
業務類別
|
Biotechnology |
|
業務概覽
|
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment. |
| 公司地址
| 1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036 |
| 電話號碼
| +1 332 255-9818 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.imux.com |
| 員工數量
| 77 |
| Dr. Daniel Vitt, PhD |
Director and Chief Executive Officer |
美元 610.00K |
26/02/2026 |
| Mr. Glenn Whaley |
Chief Financial Officer and Principal Accounting Officer |
美元 445.00K |
26/02/2026 |
| Dr. Andreas Muehler |
Chief Medical Officer |
美元 500.00K |
22/04/2025 |
| Dr. Hella Kohlhof |
Chief Scientific Officer |
-- |
22/04/2025 |
| Mr. Inderpal Singh |
General Counsel |
-- |
22/04/2025 |
| Mr. Patrick Walsh |
Chief Business Officer |
-- |
22/04/2025 |
| Mr. Jason Tardio, M.B.A. |
Chief Operating Officer and President |
美元 250.00K |
22/04/2025 |
| Mr. Werner Gladdines |
Chief Development Officer |
-- |
22/04/2025 |
|
|
| Mr. Barclay A. Phillips |
Lead Independent Director |
26/02/2026 |
| Ms. Tamar D. Howson |
Independent Director |
26/02/2026 |
| Ms. Simona Skerjanec, M.B.A. |
Interim Chairman of the board |
13/02/2026 |
| Dr. Duane D. Nash, M.D. |
Director |
13/02/2026 |
| Mr. Thorvald Nagel |
Director |
13/02/2026 |
| Dr. Daniel Vitt, PhD |
Director and Chief Executive Officer |
26/02/2026 |
| Dr. Jorg Neermann, PhD |
Independent Director |
26/02/2026 |
| Mr. Richard Alan Rudick |
Independent Director |
26/02/2026 |
|
|
|
|
